Core Insights - Royal Philips has launched the VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter in Europe, enhancing real-time 3D imaging capabilities for cardiac procedures without the need for general anesthesia [1][6]. Product Features - The VeriSight Pro catheter is designed for procedures like transcatheter valve repair and left atrial appendage closure, providing high-resolution 2D and 3D visualization directly within heart chambers [2][4]. - It features a miniaturized ultrasound probe, approximately 3 millimeters in diameter, allowing for detailed imaging from within the heart [4][13]. - Unique technologies such as xPlane and iRotate enable simultaneous visualization of two imaging planes and digital adjustments without repositioning the catheter [8]. Clinical Impact - The introduction of VeriSight Pro addresses the growing challenge of structural heart disease in Europe, facilitating procedures that traditionally required general anesthesia and extended recovery times [3][5]. - The catheter reduces the burden on patients and healthcare facilities by shortening hospital stays and lowering costs associated with traditional imaging methods [3][5]. Integration and Ecosystem - VeriSight Pro is part of Philips' integrated portfolio for structural heart care, working seamlessly with EPIQ ultrasound systems and the Azurion image-guided therapy platform [7]. - This integration supports a comprehensive solution for various cardiac procedures, enhancing workflow and clinical outcomes [7]. Upcoming Events - Philips will showcase the VeriSight Pro at EuroPCR 2025 in Paris, highlighting its application in real-world structural heart procedures [9][14].

May 15, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful pricing of its offering of EUR 500 million fixed rate notes due 2030 and EUR 500 million fixed rate notes due 2035 (the “Notes”) under its European Medium Term Note (EMTN) program. The net proceeds will be used for general corporate purposes, the repayment of 2026 debt maturities, and to refinance or finance any Eligible Projects as defined in Philips’ Sustaina ...

Core Insights - The Future Health Index 2025 report by Royal Philips highlights the urgent need for healthcare transformation, emphasizing AI's potential to alleviate care delays and manage data overload, while also noting significant trust gaps among clinicians and patients that could hinder adoption [1][2][5] Group 1: Healthcare Delivery Challenges - Over half of the 16 surveyed countries report patients waiting nearly two months or more for specialist appointments, with waits in Canada and Spain extending to four months or longer [2] - 33% of patients have experienced worsening health due to delays in seeing a doctor, and more than 25% end up hospitalized due to long wait times [3] - A projected shortfall of 11 million health workers by 2030 could exacerbate the issue of timely care [3] Group 2: Clinician Burden and AI Potential - More than 75% of healthcare professionals report losing clinical time due to incomplete or inaccessible patient data, with one-third losing over 45 minutes per shift, equating to 23 full days lost annually [4] - Clinicians view AI as a potential solution to these inefficiencies, but delayed adoption poses risks [4] Group 3: Trust and Adoption Barriers - There is a significant trust gap, with 34% more clinicians recognizing AI's benefits compared to patients, particularly among those aged 45 and older [5] - 69% of clinicians are involved in AI development, but only 38% believe these tools meet real-world needs, with over 75% unclear about liability for AI-driven errors [5] - Data bias is a major concern, risking the deepening of healthcare disparities if not addressed [5] Group 4: Future Directions for AI in Healthcare - Patients desire AI to enhance safety, reduce errors, and improve outcomes, while clinicians emphasize the need for clear legal and ethical standards, strong scientific validation, and continuous oversight [6] - Regulatory frameworks must evolve to balance innovation with patient safety and foster trust among clinicians [7] - By 2030, AI could potentially double patient capacity by automating administrative tasks [7]

Google Cloud helps streamline marketing processes, enhancing brand consistency and reducing operational costsAMSTERDAM and SUNNYVALE, Calif., May 14, 2025 /PRNewswire/ -- Google Cloud today announced a collaboration with the Philips Personal Health Business to modernize its global image library and content marketing systems. Leveraging Google Cloud's Vertex AI platform, Philips has developed a solution that enables asset management with unprecedented speed and scale, significantly reducing operational costs ...

Core Points - Royal Philips announced that shareholders approved all proposals at the Annual General Meeting of Shareholders (AGM) 2025 [1][4] - The Supervisory Board welcomed Bob White as a new member and re-appointed Indra Nooyi and Chua Sock Koong [1][4] - Marnix van Ginneken was re-appointed as a member of the Board of Management [1][4] Resolutions Taken at AGM 2025 - Adoption of the financial statements for 2024 and a dividend of EUR 0.85 per common share [6] - Positive advisory vote on the approval of the Remuneration Report 2024 [6] - Discharge of the members of the Board of Management and Supervisory Board [6] - Appointment of Marnix van Ginneken to the Board of Management effective May 8, 2025 [6] - Re-appointment of Chua Sock Koong and Indra Nooyi to the Supervisory Board effective May 8, 2025 [6] - Appointment of Bob White to the Supervisory Board effective May 8, 2025 [6] - Authorization for the Board of Management to issue shares and acquire shares in the company [6] Company Overview - Royal Philips is a leading health technology company focused on improving health and well-being through innovation [8] - The company generated sales of EUR 18 billion in 2024 and employs approximately 67,200 employees [8]

Koninklijke Philips N.V. (PHG) reported earnings of €0.08 cents per share in the first quarter of 2025, which increased from the year-ago quarter’s loss of €1.07 per share.The company’s sales decreased 1% on a year-over-year basis to €4.1 billion.Comparable sales declined 2% year over year, including a double-digit decline in China. The 1% growth in Personal Health was more than offset by a 4% decline in Diagnosis & Treatment on the back of a high comparison base. Connected Care sales were in line with the ...

报名：首届全球心血管大会 | 最新议程 合作伙伴征集：2025全球手术机器人大会 2025年5月6日，飞利浦公布了2025年第一季度最新财报。此前公司表示，美国与中国（以及其他国家和 地区）之间的关税将对今年的业绩产生 2.5亿至3亿欧元的影响。 飞利浦在财报中 维持了其可比销售额增长1%至3%的预期，但将其全年调整后的EBITDA利润率预期从 11.8%至12.3%下调至 10.8%至11.3%。 # 财 报亮点 # 业务详情 | | Q1 2024 | Q1 2025 | | --- | --- | --- | | Sales | 2,026 | 1,965 | | Nominal sales growth | 1% | (3%) | | Comparable sales growth 1 | 3% | (4%) | | Income from operations | 146 | 153 | | as a % of sales | 7.2% | 7.8% | | EBITA 1 | 168 | 173 | | as a % of sales | 8.3% | 8.8% | | Adjusted EBIT ...

Koninklijke Philips NV PHG reported first-quarter 2025 adjusted earnings per share of 26 cents (or 0.25 euros), beating the consensus of 20 cents.The Dutch healthcare technology group reported quarterly sales of $4.31 billion (4.09 billion euros), beating the consensus of $4.10 billion.Comparable sales decreased by 2%, including a double-digit decline in China.Diagnosis & Treatment comparable sales decreased by 4%, due to a double-digit decline in China and on the back of a high comparison base in prior yea ...

Financial Performance - Group sales for Q1 2025 were EUR 4.1 billion, reflecting a 2% decline in comparable sales growth primarily due to a double-digit decline in China[17]. - Comparable order intake increased by 2%, driven by strong performance in North America, offsetting the decline in China[12]. - Adjusted EBITA margin decreased by 80 basis points to 8.6%, mainly due to the decline in sales, with income from operations increasing to EUR 154 million[14]. - Free cash flow was an outflow of EUR 1,091 million, primarily due to a EUR 1,025 million payment related to Philips Respironics recall settlements[14]. - Personal Health segment saw a 1% increase in comparable sales, while Diagnosis & Treatment experienced a 4% decline[27]. - The overall sales for the Philips Group decreased slightly from EUR 4,138 million in Q1 2024 to EUR 4,097 million in Q1 2025[44]. - Income from operations for the Philips Group turned positive at EUR 154 million in Q1 2025, compared to a loss of EUR 824 million in Q1 2024[44]. - Net income attributable to shareholders improved from a loss of EUR 999 million in Q1 2024 to a profit of EUR 76 million in Q1 2025[45]. - The total comprehensive income for the period improved from a loss of EUR 693 million in Q1 2024 to a loss of EUR 362 million in Q1 2025[46]. - Net income for Q1 2025 was €72 million, a significant recovery from a net loss of €998 million in Q1 2024[54]. - Adjusted income from continuing operations attributable to shareholders for Q1 2025 was €237 million, compared to €235 million in Q1 2024[54]. - Free cash flow for Q1 2025 was negative €1,091 million, worsening from negative €336 million in Q1 2024[57]. - Comparable sales growth for the Philips Group in Q1 2025 was negative 2.3%, with Diagnosis & Treatment segment declining by 4.3%[53]. - The company reported a decrease in working capital, with a reduction of €216 million in Q1 2025 compared to a decrease of €526 million in Q1 2024[54]. - Total comprehensive loss for Q1 2024 was €695 million, while for Q1 2025, it was a loss of €358 million[50]. - The company incurred restructuring and acquisition-related charges of €67 million in Q1 2025, up from €51 million in Q1 2024[54]. - Cash flows from operating activities were negative €933 million in Q1 2025, compared to negative €171 million in Q1 2024[57]. Sales and Market Performance - Connected Care sales increased from EUR 1,164 million in Q1 2024 to EUR 1,182 million in Q1 2025, showing a nominal sales growth of 2%[32]. - Personal Health sales rose from EUR 790 million in Q1 2024 to EUR 811 million in Q1 2025, reflecting a nominal sales growth of 3%[33]. - Comparable sales growth for Q1 2024 was 2%, while comparable order intake decreased by 4%[59]. - Philips reported Q1 2024 sales of €4,138 million, reflecting a nominal sales decline of 1% compared to the previous year[59]. Cost Management and Productivity - Productivity initiatives delivered savings of EUR 147 million in Q1 2025, contributing to a total of over EUR 1.9 billion in savings since 2023[19]. - Other segment's adjusted EBITA improved to EUR 187 million with a margin of 9.5% despite lower sales, driven by productivity measures[34]. Future Outlook - Philips' outlook for full year 2025 includes an estimated net tariff impact of EUR 250-300 million, with an adjusted EBITA margin range of 10.8%-11.3%[24]. - The company anticipates that 2025 performance will be skewed toward the latter part of the year, with Q2 showing modest improvement from Q1[24]. - The company anticipates future sales growth and improvements in adjusted EBITA, while facing risks from macro-economic and geopolitical changes[37][38]. Innovation and Technology - Philips was recognized as the leading applicant in medical technology at the European Patent Office in 2024, highlighting its commitment to innovation[23]. - New AI technologies were introduced to enhance imaging and patient outcomes, including advanced algorithms in MRI systems and ultrasound[23]. Balance Sheet and Financial Ratios - Total current assets decreased from EUR 10,022 million at the end of 2024 to EUR 8,669 million by March 31, 2025[48]. - Total liabilities for the Philips Group decreased from EUR 16,933 million at the end of 2024 to EUR 15,439 million by March 31, 2025[48]. - The net debt to group equity ratio increased from 30:70 as of December 31, 2024, to 35:65 as of March 31, 2025[58]. - Total cash and cash equivalents decreased from €2,401 million at the beginning of Q1 2025 to €1,193 million by the end of the period[58]. - The net debt to group equity ratio improved to 36:64 by Q1 2024[59]. - Total employees at Philips decreased to 69,062 by the end of Q1 2024[59].

尽管飞利浦下调了利润预期，但重申了今年1%至3%之间的可比销售增长预测。财报公布后，飞利浦股 价在早盘交易中一度跌逾4%。 关税阴云笼罩 鉴于美国是飞利浦最大的市场，后者正面临特朗普政府快速变化的贸易策略带来的挑战。 据媒体统计，美国市场约占飞利浦2024年预计销售额的40%和税收贡献的三分之一，公司进口 Respironics呼吸面罩、电动剃须刀、牙刷和其他设备等多种医疗设备。 面临关税压力，飞利浦下调全年利润预期。 周二美股盘前，荷兰医疗科技巨头飞利浦公布2025年Q1财报，一季度销售额为41亿欧元，同比下降 2%，高于分析师平均预期的40.2亿欧元。 声明表示，由于日益严峻的贸易壁垒成本，公司将下调全年盈利预期。预计调整后的营业利润率将在 10.8%至11.3%之间，比先前预期下降了100个基点。 公司表示，尽管已采取"大量关税缓解措施"，但关税政策仍将带来2.5亿至3亿欧元(约合2.83亿至3.4亿美 元)的净影响。 据报道，飞利浦正在加速其在美国46个工厂的生产，并进一步本地化其在中国的业务。 值得注意的是，关于医疗保健行业的关税税率和时间点仍不明确，分析师预计，如果这些关税被实施， 公司很可能需要 ...